Search
15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference
October 26-31, 2020 | Virtual Global Conference
Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty, R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell
In the last week of October, consultants and specialist psychologists, nurses, scientists and…
EHA has joined the European Cancer Organisation - a perfect match on objectives and prioritization
The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level.
Read moreStrategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition
PRESS RELEASE
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition
The Hague, Wednesday 18, November, 2020
The field of cell and gene therapy is one of the most…
EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
EHA IN COLLABORATION WITH BALTIC SOCIETIES CONCLUDE THE FIRST HYBRID TUTORIAL MEETING IN EHA HISTORY!
EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
August 28 – 30, 2020
Virtual & Riga, Latvia
Meeting Chairs:
Prof S Eichinger (European Hematology Association)
Prof S Lejniece (Latvian Society of…
Call for urgent action on medicine shortages in Europe
Medicine shortages are an increasing problem across Europe, posing a severe threat to patient outcomes and patient safety. In a new position paper the European Public Health Alliance (EPHA) presents nine recommendations for addressing the shortages crisis.
Read moreGuidelines for hematologists
For guidance regarding COVID-19, see FAQ by the EHA SWG on Infections
EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases.
EHA statement on coronavirus (COVID-19)
The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).
Read moreATMPs and CAR-T: the uptake challenge
Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.
Read moreEU health policy: limited scope, high ambition
Over the past decades, the European Union (EU) has become more involved in public health policy. A recent study showed that a majority of policymakers even identifies EU health policy as a priority for 2020-20241.
Read moreRevising the ICH Guidelines on Clinical Trials
The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.
Read more